Education
About Us
Working with TipRanks
Follow Us
Noxopharm Ltd. (AU:NOX)
ASX:NOX
NOX Stock Chart & Stats
AU$0.09
>-AU$0.01(-8.99%)
At close: 4:00 PM EST
AU$0.09
>-AU$0.01(-8.99%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.14
Previous CloseN/A
Volume154.85K
Average Volume (3M)123.50K
Market Cap
AU$21.92M
Enterprise ValueAU$22.84M
Total Cash (Recent Filing)AU$1.55M
Total Debt (Recent Filing)AU$2.48M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding292,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oncology-focused R&D PlatformNoxopharm’s clear focus on small-molecule oncology assets that enhance radiotherapy and immuno-oncology is a durable strategic position. A targeted R&D platform creates technical differentiation, multiple asset optionality and long-term licensing or partnership potential in a structurally growing oncology market.
Revenue Recovery In 2025After a prior sharp decline, revenue rising ~20% in 2025 indicates improving commercial or milestone receipts. A sustained top-line recovery can extend runway and validate pipeline progress, supporting longer-term program funding and partner interest if maintained beyond a single reporting period.
Active External Partnering StrategyExplicit engagement with external partners is a structural advantage for a small biotech: it can de-risk clinical development, provide non-dilutive capital or co-development resources, and accelerate commercialization pathways, improving long-term probability of asset progression and market entry.
Bears Say
Materially Weakened Balance SheetLeverage rising to roughly 3.6x equity materially reduces financial flexibility. Higher debt and diminished equity heighten refinancing and covenant risk, increase interest burdens, and limit the company’s ability to self-fund expensive oncology trials over the medium term without dilutive financing or partner deals.
Persistent Heavy Cash BurnConsistent negative operating and free cash flow indicate the business cannot self-sustain development spending. Persistent burn requires repeated capital raises or partner funding, which can dilute shareholders, constrain strategic choices and slow clinical programs if funding terms deteriorate.
Ongoing Losses And Negative Gross ProfitNegative gross profit and large operating losses show the core economics are unfavorable today. Without structural improvement in margins or recurring revenue sources, the company faces long-term sustainability issues and must achieve meaningful clinical or commercial milestones to alter its loss trajectory.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.04 and its highest was AU$0.14 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$21.92M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Mar 03, 2026 which is in 14 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Aug 28, 2025. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.012.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 292,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.50%
12-Months-Change
Fundamentals
Return on Equity
-157.93%
Trailing 12-Months
Asset Growth
-32.46%
Trailing 12-Months
Company Description
Noxopharm Ltd.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Chimeric Therapeutics Ltd.
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―